SCHEMBL5136177

SCHEMBL5136177

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1OCC)CC1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
TSHR P16473 4/20 0.35
CCR4 P51679 2/20 0.35
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 4/20 0.34
HSD17B10 Q99714 4/20 0.34
HPGD P15428 3/20 0.34
CYP3A4 P08684 3/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HDAC1 Q13547 1/20 0.34
ADORA3 P0DMS8 2/20 0.34
ADORA2A P29274 2/20 0.34
ADORA2B P29275 2/20 0.34
ADORA1 P30542 2/20 0.34
MAPT P10636 1/20 0.34
POLB P06746 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
BCHE P06276 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137556 0.92 C5AR1 (0.40) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL650011 0.89 C5AR1 (0.38) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL5136466 0.89 C5AR1 (0.42) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL648592 0.88 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HSD17B10
SCHEMBL651501 0.87 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1HSD17B10
SCHEMBL5136106 0.87 C5AR1 (0.41) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL5136793 0.87 C5AR1 (0.41) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL5135152 0.87 C5AR1 (0.41) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL5137310 0.87 C5AR1 (0.41) C5AR1TSHRCCR4KDM4EALDH1A1
SCHEMBL5137575 0.86 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed